Beta-adrenergic blocking drugs in breast cancer: A perspective review

Thomas I. Barron, Linda Sharp, Kala Visvanathan

Research output: Contribution to journalArticle

Abstract

The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and breast cancer progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signalling can inhibit multiple cellular processes involved in breast cancer progression and metastasis, including extracellular matrix invasion, expression of inflammatory and chemotactic cytokines, angiogenesis and tumour immune responses. This has led to the hypothesis that the commonly prescribed class of β-AR antagonist drugs (β-blockers) may favourably impact cancer progression. A number of recent pharmacoepidemiological studies have examined the association between β-blocker exposure and breast cancer progression. The results from these studies have suggested a potential role for targeting the β-AR pathway in breast cancer patients. Larger observational studies are, however, required to confirm these results. Questions regarding the type of β-blocker, predictive biomarkers or tumour characteristics, appropriate treatment paradigms and, most importantly, efficacy must also be answered in randomized clinical studies before β-blockers can be considered a therapeutic option for patients with breast cancer.

Original languageEnglish (US)
Pages (from-to)113-125
Number of pages13
JournalTherapeutic Advances in Medical Oncology
Volume4
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Adrenergic Agents
Breast Neoplasms
Tumor Biomarkers
Chemokines
Adrenergic Receptors
Observational Studies
Extracellular Matrix
Neoplasms
Neoplasm Metastasis
Therapeutics
Pharmaceutical Preparations

Keywords

  • Adrenergic beta-agonists
  • Adrenergic beta-antagonists
  • Adrenergic receptors
  • Breast neoplasms
  • Neoplasms
  • Propranolol

ASJC Scopus subject areas

  • Oncology

Cite this

Beta-adrenergic blocking drugs in breast cancer : A perspective review. / Barron, Thomas I.; Sharp, Linda; Visvanathan, Kala.

In: Therapeutic Advances in Medical Oncology, Vol. 4, No. 3, 05.2012, p. 113-125.

Research output: Contribution to journalArticle

@article{64bfe179c31847ce85be1ecc92df3b6e,
title = "Beta-adrenergic blocking drugs in breast cancer: A perspective review",
abstract = "The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and breast cancer progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signalling can inhibit multiple cellular processes involved in breast cancer progression and metastasis, including extracellular matrix invasion, expression of inflammatory and chemotactic cytokines, angiogenesis and tumour immune responses. This has led to the hypothesis that the commonly prescribed class of β-AR antagonist drugs (β-blockers) may favourably impact cancer progression. A number of recent pharmacoepidemiological studies have examined the association between β-blocker exposure and breast cancer progression. The results from these studies have suggested a potential role for targeting the β-AR pathway in breast cancer patients. Larger observational studies are, however, required to confirm these results. Questions regarding the type of β-blocker, predictive biomarkers or tumour characteristics, appropriate treatment paradigms and, most importantly, efficacy must also be answered in randomized clinical studies before β-blockers can be considered a therapeutic option for patients with breast cancer.",
keywords = "Adrenergic beta-agonists, Adrenergic beta-antagonists, Adrenergic receptors, Breast neoplasms, Neoplasms, Propranolol",
author = "Barron, {Thomas I.} and Linda Sharp and Kala Visvanathan",
year = "2012",
month = "5",
doi = "10.1177/1758834012439738",
language = "English (US)",
volume = "4",
pages = "113--125",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Beta-adrenergic blocking drugs in breast cancer

T2 - A perspective review

AU - Barron, Thomas I.

AU - Sharp, Linda

AU - Visvanathan, Kala

PY - 2012/5

Y1 - 2012/5

N2 - The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and breast cancer progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signalling can inhibit multiple cellular processes involved in breast cancer progression and metastasis, including extracellular matrix invasion, expression of inflammatory and chemotactic cytokines, angiogenesis and tumour immune responses. This has led to the hypothesis that the commonly prescribed class of β-AR antagonist drugs (β-blockers) may favourably impact cancer progression. A number of recent pharmacoepidemiological studies have examined the association between β-blocker exposure and breast cancer progression. The results from these studies have suggested a potential role for targeting the β-AR pathway in breast cancer patients. Larger observational studies are, however, required to confirm these results. Questions regarding the type of β-blocker, predictive biomarkers or tumour characteristics, appropriate treatment paradigms and, most importantly, efficacy must also be answered in randomized clinical studies before β-blockers can be considered a therapeutic option for patients with breast cancer.

AB - The purpose of this review is to present the preclinical, epidemiological and clinical data relevant to the association between β-blockers and breast cancer progression. Preclinical studies have shown that β-adrenergic receptor (β-AR) signalling can inhibit multiple cellular processes involved in breast cancer progression and metastasis, including extracellular matrix invasion, expression of inflammatory and chemotactic cytokines, angiogenesis and tumour immune responses. This has led to the hypothesis that the commonly prescribed class of β-AR antagonist drugs (β-blockers) may favourably impact cancer progression. A number of recent pharmacoepidemiological studies have examined the association between β-blocker exposure and breast cancer progression. The results from these studies have suggested a potential role for targeting the β-AR pathway in breast cancer patients. Larger observational studies are, however, required to confirm these results. Questions regarding the type of β-blocker, predictive biomarkers or tumour characteristics, appropriate treatment paradigms and, most importantly, efficacy must also be answered in randomized clinical studies before β-blockers can be considered a therapeutic option for patients with breast cancer.

KW - Adrenergic beta-agonists

KW - Adrenergic beta-antagonists

KW - Adrenergic receptors

KW - Breast neoplasms

KW - Neoplasms

KW - Propranolol

UR - http://www.scopus.com/inward/record.url?scp=84864420773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864420773&partnerID=8YFLogxK

U2 - 10.1177/1758834012439738

DO - 10.1177/1758834012439738

M3 - Article

C2 - 22590485

AN - SCOPUS:84864420773

VL - 4

SP - 113

EP - 125

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 3

ER -